Clinical trial
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable…
NCT00398320 · Pamela L. Kunz, Other · Completed
Key facts
| NCT number | NCT00398320 |
|---|---|
| Title | Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors |
| Official title | A Phase II Study of Capecitabine, Oxaliplatin and Bevacizumab for Metastatic or Unresectable Neuroendocrine Tumors |
| Lead sponsor | Pamela L. Kunz, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumors |
| Intervention type | Drug |
| Interventions | Capecitabine, Oxaliplatin, Bevacizumab |
| Enrollment | 40 |
| Start date | Nov 1, 2006 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Nov 10, 2006 |
| Last update posted | Mar 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: